These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36187655)

  • 1. Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China.
    Liu J; Cao L; Wu J
    Front Public Health; 2022; 10():987408. PubMed ID: 36187655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.
    Rajagopalan K; Trueman D; Crowe L; Squirrell D; Loebel A
    Pharmacoeconomics; 2016 Jul; 34(7):709-21. PubMed ID: 27067724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.
    Ng-Mak D; Messali A; Huang A; Wang L; Loebel A
    Am J Manag Care; 2019 Jul; 25(14 Suppl):S279-S286. PubMed ID: 31365818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
    Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
    J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US.
    O'Day K; Rajagopalan K; Meyer K; Pikalov A; Loebel A
    Clinicoecon Outcomes Res; 2013; 5():459-70. PubMed ID: 24049452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.
    Zhao J; Jiang K; Li Q; Zhang Y; Cheng Y; Lin Z; Xuan J
    J Med Econ; 2019 May; 22(5):439-446. PubMed ID: 30732487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
    Davies A; Vardeva K; Loze JY; L'italien GJ; Sennfalt K; Baardewijk Mv
    Curr Med Res Opin; 2008 Nov; 24(11):3275-85. PubMed ID: 18947458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
    Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
    De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
    Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
    Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
    Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic model to understand the cost-effectiveness of olanzapine orally dispersible tablets (ODT) and olanzapine film coated tablets as a group compared with other oral atypical antipsychotics for treating schizophrenia in Morocco.
    Tazi A; Errachidi F; Sonawane D; Tahri G; Rao S; Mehta S
    Ann Gen Psychiatry; 2024 Sep; 23(1):33. PubMed ID: 39294740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom.
    Dymond A; Afonso D; Green W
    BMC Health Serv Res; 2022 Aug; 22(1):1084. PubMed ID: 36002828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
    Laux G; Heeg B; van Hout BA; Mehnert A
    Pharmacoeconomics; 2005; 23 Suppl 1():49-61. PubMed ID: 16416761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
    Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
    J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
    Ascher-Svanum H; Furiak NM; Lawson AH; Klein TM; Smolen LJ; Conley RR; Culler SD
    J Med Econ; 2012; 15(3):531-47. PubMed ID: 22304338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
    Rajagopalan K; Wade S; Meyer N; Loebel A
    Curr Med Res Opin; 2017 May; 33(5):813-820. PubMed ID: 28098496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.